Cereno scientific therapeutic areas
WebCereno Scientific AB develops drugs that normalize the body's own defense system against blood clots for the treatment of complications in cardiovascular diseases. Lists Featuring This Company European Union (EU) Health Care Companies (Top 10K) 9,796 Number of Organizations • $64.1B Total Funding Amount • 9,006 Number of Investors … WebSep 9, 2024 · Cereno Scientific (XSAT: CRNO B) today announced that a patent has been allowed in the second patent family for the preclinical Prostacyclin Receptor Agonist Program, which includes drug candidate CS585. ... granted a patent in the US in its first patent family titled “Hydroxyeicosatrienoic acid compounds and their use as therapeutic …
Cereno scientific therapeutic areas
Did you know?
WebCereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease... WebAt a glance Originator Cereno Scientific Class Anti-ischaemics; Antiarrhythmics; Antiepileptic drugs; Antimigraines; Antithrombotics; Cardiovascular therapies; Nootropics; Pentanoic acids; Small molecules; Vascular disorder therapies
WebCereno invites analysts, investors, and financial media to join us for insights into our strategy and operations. CMD 2024 Event Agenda Event The Capital Markets Day 2024 was held on Tuesday, August 30, 2024, at 14:30-17:30 at Helio GT30, Grev Turegatan 30, in Stockholm. Access the video recording of the event > WebMay 17, 2024 · In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US.
WebApr 5, 2024 · Born 1953. Björn Dahlöf is Cereno’s Chief Medical Officer since 2024 and has for many years been an adviser to small and large pharmaceutical companies regarding drug development in all phases from preclinical development to larger lifecycle management studies after registration. Björn Dahlöf has extensive experience in cardiovascular … WebCereno Scientific AB BioVentureHub Pepparedsleden 1 431 83 Mölndal, Sverige. Email: [email protected] Corp. Reg. No.: 556890–4071. Investor queries. Josefine Göranson, Head of IR & Communication Email: [email protected] Phone: +46 (0)704 92 35 63
WebDeveloping innovative treatments for patients affected by common and rare cardiovascular diseases. Cereno Scientific is a clinical stage biotech company within cardiovascular diseases.
WebApr 13, 2024 · Born 1977. Jonas Faijerson Säljö has a research background in the stroke area with wide-ranging experience in the commercialization of medical innovations. Faijerson Säljö has significant expertise in intellectual property and business development experience from a large number of companies in the life science area. He is currently … recreation tcnjWebDec 10, 2024 · Cereno Scientifics aim is to form a platform of drug candidates that affects the field of epigenetic modulation through "HDAC inhibition" (Histone DeACetylase inhibition). The company's first program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. recreation teacherWebJun 14, 2024 · Cereno Scientific is a biotech company focusing on developing innovative treatments for patients affected by common and rare cardiovascular diseases. Cardiovascular disease is the number 1 cause of death globally, killing nearly twice as many people as cancer. upchuck and the rotten willy reading levelrecreation technicianWebIn connection to the directed issue that was completed in September 2024 a total of 34,519,281 warrants of series TO2 was issued. Each warrant of series TO2 will give the holder the right to subscribe for one new share of series B in Cereno during the period from 14 September 2024 until and including 28 September 2024 to a subscription price ... recreation tax creditWebNov 16, 2024 · Cereno Insights Series: CS1 -PAH Clinical Trial Design with Sörensen, Dahlöf & Adamson Presentation 24 Nov 2024 Infocus interview and presentation at Redeye Life Science Day Interview 16 Nov 2024 CEO interview in conjunction with the Q3 report 2024 (Swedish) Presentation 14 Sep 2024 Company presentation and Q&A at BioStock … recreation taxidermyWebApr 3, 2024 · Cereno has a project portfolio targeting common and rare cardiovascular diseases. The aim is to develop treatments that can improve the life for affected patients. The portfolio comprises a Phase II program and two preclinical programs. Read more. … Cereno Scientific is a clinical-stage biotech company within common and rare … Therapeutic focus. Cereno focuses on epigenetic modulation in cardiovascular … 16th Global Cardiovascular Clinical Trialists Forum Faiez Zannad and Bertram Pitt, … Cereno Scientific is a biotech company focusing on developing innovative … The extraordinary General Meeting of Cereno Scientific AB (Publ) took place … Career. Cereno Scientific is a clinical-stage biotech company within common and … Cereno Scientific AB BioVentureHub Pepparedsleden 1 431 83 Mölndal, … BIO-Europe 2024 Cereno Scientific will attend BIO-Europe 2024. Contact Sten … 16th Global Cardiovascular Clinical Trialists Forum Faiez Zannad and Bertram Pitt, … upchuck and molestache